The mystery to me still seems to be exactly where we are at with...

The mystery to me still seems to be exactly where we are at with fpp. The question being after much talk from various places what are the true facts with fpp. Are our best fpp's still generally absorbed by the first human cells they come into contact with or have we found some way to specifically target a cell type. In the early days i got the impression that somehow it was possible to create or program a fpp to only enter diseased or cancer cells and leave healthy cells alone. Probably thanks to bioexec i got the impression that the majority of fpp/cpp that can enter human cells will enter any human cells they contact indescrimenately. Tbe challenge is to minimise the effect in healthy cells and maximise the effect in damaged or cancerous cells. If nothing has changed then the issue is not entering cells and escaping endosome but actually being able to target specific cell types, or at least minimise effect on healthy cells contacted. This is the one thing i think that still hasnt been touched on in any of the recent announcements. If we are entering any human cell we contact then toxicity and absortion rates are just as critical as endosomal escape. Its been said a few times but mouse model seems to be a low bar compared to what happens if you pump a myc inhibiting fpp into human bloodstream and it enters every cell it contacts.

Pyc can you provide update on how specific our lead fpp absorbtion is to human cells. Can we target a particular type of cell or is it all or nothing.